drugset / Trial / NCT01959841
Phase III Study of ASP2151 in Herpes Zoster Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in patients with herpes zoster.
Timeline
- Start
- 2013-08
- Primary completion
- 2015-07
- Completion
- 2015-07-10
Outcome
Met primary endpoint
registry NUMBER Valaciclovir: 75.1 percentage of Participants NCT01959841 ↗
registry analysis (non-inferiority test); ASP2151(400mg) vs Valaciclovir; p = 0.00000241; Modified Farrington-Manning test NCT01959841 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amenamevir | Small molecule | 200 mg | — |
| Subject | Amenamevir | Small molecule | 400 mg | — |
| Subject | Valaciclovir | Unknown | 1000 mg | — |